benserazide has been researched along with Cognition Disorders in 2 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than ." | 1.28 | Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. ( Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masson, H | 1 |
| Popescu, I | 1 |
| Strubel, D | 1 |
| Cramer, H | 1 |
| Kuntzmann, F | 1 |
| Rayevsky, KS | 1 |
| Bondarenko, NA | 1 |
| Kudrin, VS | 1 |
| Miroshnichenko, II | 1 |
2 other studies available for benserazide and Cognition Disorders
| Article | Year |
|---|---|
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid; | 1990 |
Cognitive deficiency induced by the acute stress in rats: a possible role of brain catecholaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; | 1990 |